Know These 4 Crucial Signs of Heatstroke and What to Do Before It's Too Late
The first heat wave of this summer is already breaking heat records across the US, with temperatures climbing higher earlier than expected. If you're spending time outdoors, whether for work or recreation, it's critical to know the risks of heat-related illness. Heatstroke, the most dangerous of them, can set in quickly and become life-threatening without warning.
It doesn't just happen to athletes or people doing intense physical activity. Classic heatstroke can occur simply by being in a hot environment for too long. According to the U.S. Department of Labor, people who work outside are especially vulnerable in the first few days of exposure, because the body needs time to adapt to rising temperatures. As the heat intensifies this summer, understanding how to spot and respond to heatstroke could be the most important safety step you take.
In addition to workers, heatstroke is especially common among the elderly, very young children, including babies, and in times "when we see these heat waves that go on for several days," Dr. Korin Hudson, an emergency room physician with MedStar Health, told CNET last year.
People with certain medical conditions and those taking certain medications or drugs, including alcohol, may also have a higher risk of heatstroke.
Here's what to know if you or someone near you starts experiencing symptoms of heatstroke.
Heatstroke symptoms
Sometimes, heatstroke can start with symptoms of heat exhaustion, which isn't quite as serious as heatstroke but still requires someone to cool down as quickly as possible. If left untreated, heat exhaustion can progress to heatstroke, which is a medical emergency. If your symptoms worsen, last more than one hour or you start vomiting, call 911.
Symptoms of heatstroke, according to the Mayo Clinic and the US Centers for Disease Control and Prevention, include:
Altered mental state, including confusion, agitation and slurred speech (this may also result in "odd" behavior)
Headache
Hot, flushed, usually dry skin (or, alternatively, heavy sweating -- if brought on by exercise, heatstroke may include moist skin)
Loss of consciousness
Racing heartbeat
Rapid breathing
Seizures
Very high body temperature
Vomiting
Keeping hydrated by drinking enough water, both before you head outdoors and while you're out in the heat, is an important step to warding off heat illness.1. Call 911
Having heatstroke is a medical emergency that requires professional care.
If there's more than one person around to aid the person suffering heatstroke, Hudson advised that one person call 911 while the other helps the person through the steps below.
2. Get to a cooler area immediately
If you're around someone who has heatstroke, move them to a cooler area, such as a nearby air-conditioned room or into the shade.
Either way, "try to move them out of the heat as quickly as possible," Hudson said. The goal is to cool down the body's core temperature.
3. Take off excess clothing
Removing long-sleeve shirts, pants or other clothing will help a person cool down faster. Hudson said the goal is to reach "evaporative cooling," and clothing can prevent evaporation.
(For people who choose to run in layers to "sweat off weight," Hudson said, you probably shouldn't. It's dangerous and can lead to heatstroke. You may consider cooling clothes that work with your body to keep you cooler and more comfortable.)
4. Hold ice, cold towels or cool water to the skin
If you have something like a cold towel or a water bottle, put it on your or the other person's neck, armpits or groin.
While you wait for help to arrive, you can even spray them down with cold water or put them in a cold shower -- anything to cool them off. Cold water immersion or an ice bath is one treatment for heatstroke that doctors may use at the hospital.
Don't force a drink on someone experiencing heatstroke, the CDC says. This is different advice than for someone who's experiencing heat exhaustion, which typically comes before heatstroke. While someone with heat exhaustion may be given sips of water or sports drink, a person experiencing heatstroke may be confused, lose consciousness or have an altered state of consciousness.
"Because they have a depressed or altered level of consciousness, it may affect their ability to swallow safely so it's probably better not to give them anything to eat or drink," Hudson said.
Before and after heatstroke: Check on your neighbors
Some people are more susceptible to heat illness and heatstroke, such as older adults, younger children, people with mobility issues, certain health conditions and those taking certain medications, including common drugs like blood pressure or antidepressant medications.
In case of a heat wave, be especially mindful to check in with your elderly neighbor down the hall or a friend who has trouble getting around, according to Hudson.
"This is the time that we really suggest people check on their neighbors," she said. "Especially in places where people don't have access to air conditioning or don't have a way to get someplace cool."
"They may be feeling poorly but can't do anything about it," Hudson added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. "With our expertise in primary hemophagocytic lymphohistiocytosis, we understand the urgency of managing MAS quickly to improve patient outcomes," said Guido Oelkers, Chief Executive Officer at Sobi. "Gamifant is already an established therapy making a meaningful difference for patients with primary HLH, and with this approval, we are excited about the opportunity to positively impact patients affected by MAS in Still's Disease". The approval is based on results of the pooled data from two pivotal studies, the Phase 3 study (NCT05001737) and NI-0501-06 (NCT03311854). 54 percent (21/39) of patients had a complete response at Week 8, and 82% (32/39) achieved clinical MAS remission (VAS ≤1 cm) at Week 8. Safety and tolerability were consistent with previous clinical studies. In patients with HLH/MAS in Still's disease, the most common adverse events (≥20%) were viral infections, including cytomegalovirus infection or reactivation, and rash. "MAS in Still's disease is a serious and potentially life-threatening complication, marked by severe hyperinflammation and, in some cases, multi-organ failure," said Alexei A. Grom, MD, Professor of Pediatrics, Research Director Division of Rheumatology, Cincinnati Children's Hospital Medical Center. "Many patients affected by MAS—both young children and adults—face significant unmet medical needs. With Gamifant now as the first FDA-approved treatment for MAS, we have a new therapeutic option that helps control hyperinflammation and reduce our reliance on high-dose glucocorticoids." MAS, a form of HLH, is a severe complication of rheumatic diseases, occurring most frequently in Still's disease including systemic juvenile idiopathic arthritis and adult-onset Still's disease. HLH/MAS is a rare systemic disorder of interferon gamma (IFNy) driven hyperinflammation with common clinical manifestations such as high persistent fever, elevated ferritin, cytopenias, coagulopathies, and hepatosplenomegaly. Gamifant, an interferon gamma (IFNγ)–blocking antibody, is the first and only FDA approved treatment for adult and pediatric (newborn and older) patients with primary HLH with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. U.S. Indication for Gamifant® (emapalumab-lzsg) Please see the full Prescribing Information for Gamifant. About macrophage activation syndrome (MAS) Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently in Still's disease including systemic juvenile idiopathic arthritis (sJIA) – a rare systemic disorder of auto-inflammatory nature with common clinical manifestations such as daily spiking fever, typical transient cutaneous rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities and hyperferritinaemia, possibly progressing to multiple organ failure and death. MAS is classified as a secondary form of haemophagocytic lymphohistiocytosis (HLH). About Gamifant® (emapalumab-lzsg) Gamifant® (emapalumab-lzsg) is the only approved anti-interferon gamma (IFNγ) monoclonal antibody. Gamifant works by binding to and neutralizing IFNγ. When IFNγ is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour. Gamifant is approved in the US for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 28 June 2025 at 00:55 CEST. Gerard TobinHead of Investor Relations This information was brought to you by Cision The following files are available for download: FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease View original content: Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
Is Danaher's M&A Premium Already Priced In?
Danaher Corporation (NYSE: DHR) is a global science and technology innovator focused on designing, manufacturing, and marketing professional, medical, industrial, and commercial products and services. Following the 2023 spin-off of its Environmental & Applied Solutions segment (now Veralto), Danaher has transformed into a pure-play life sciences and diagnostics company, operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. Warning! GuruFocus has detected 4 Warning Signs with DHR. Biotechnology (~30% of FY2024 revenue) includes Danaher's bioprocessing and genomic reagents businesses, led by brands like Cytiva and Pall, serving pharmaceutical and biotech companies in biologics production and Sciences (~25% of revenue) offers analytical instruments, microscopy, and lab automation tools used by academic institutions, research labs, and clinical diagnostics developers. Key platforms include Leica Microsystems, SCIEX, and Beckman Coulter Life (~45% of revenue) comprises molecular diagnostics, core laboratory diagnostics, and point-of-care testing systems. Notably, Cepheidone of Danaher's flagship brandsoffers rapid molecular diagnostic testing platforms, particularly for infectious diseases like COVID-19, influenza, and tuberculosis. Danaher reported a better-than-feared quarter, beating both top and bottom line estimates significantly and maintaining its annual guidance. In Q1 FY2025, the company's total sales declined by 1% YoY to $5,741 million from $5,796 million in the previous year's quarter. The decline was due to -1.5% impact from foreign exchange translation, which was partially offset by 0.5% growth through acquisitions and flat core revenue growth. The revenue from the Biotechnology segment grew by 6% YoY to $1,612 million, driven by an increase in core sales from high-growth markets due to a rise in demand. The Life Sciences segment saw a decline of 3.5% YoY to $1,680 million due to a decrease in core sales in the genomics consumables business. Revenue from the Diagnostics segment declined by 3% YoY to $2,449 million due to a decline in the sales of the molecular diagnostic business and lower sales in the China region. The adjusted operating profit declined by 50 bps YoY to 29.6% in the quarter due to product mix, administrative cost structure, currency exchange rates, and acquisition Corporation's Growth & Cash Flow Danaher is positioned as a leading provider of life sciences, diagnostic, and biotechnology equipment after spinning off its environmental business (Veralto) in late 2023. Management's guidance for FY2025 assumes relatively stable end-market demand for the rest of the year (similar to Q1 levels). Against this backdrop, I believe Danaher should grow modestly in 2025, reflecting both macro headwinds (tariffs, academic budget cuts) and continued strength in critical segments. I have mentioned the guidance provided by the management below, and my thesis that should help the company achieve it. For fiscal 2025, Danaher reaffirmed core revenue growth of roughly +3% year-over-year. This is consistent with management's view that market demand (globally) will be relatively consistent with Q1, despite tariffs and other pressures. Adjusted diluted EPS guidance was set at $7.60$7.75 (vs. $7.68 consensus). Notably, management raised its Bioprocessing (biotech) growth forecast to the high-single-digits for 2025 (from a prior 67% outlook). Bioprocessing is Danaher's fastest-growing segment. Robust demand for biologic drug development kits and reagents drove higher Q1 results and should continue to drive growth for the remainder of FY2025. Furthermore, the segment is emerging from the destocking cycle, which should help drive sales. In contrast, the Life Sciences segment forecast was trimmed to essentially flat growth, as funding uncertainties slowed academic and government sales (particularly in the U.S.), and China's medical equipment sector has experienced some softness. This should offset the healthy growth in the Bioprocessing segment. However, any rebound in global R&D spending (or continued Chinese stimulus) could surprise on the upside. The Diagnostics segment (especially Cepheid's molecular tests) is expected to see modest growth: Cepheid's respiratory test sales are forecast to reach around $1.7 billion for 2025, but production volume will return to a normal seasonal level after Q1. Overall, Danaher's portfolio remains tilted toward high-growth medical and diagnostics markets, which underpins its steady outlook despite industry headwinds. A key uncertainty is trade policy: Danaher estimates that current U.S. and European tariffs could add roughly $350 million in costs in 2025. However, the company has long worked to offset these costs via its Danaher Business System (DBS), regionalized manufacturing, and pricing strategies. The company should absorb much of the tariff impact through cost actions and supply-chain adjustments (e.g., surcharges or shifting production) rather than curtailing R&D or major initiatives. Because Danaher's products (lab instruments, diagnostics, and biotech consumables) are often mission-critical in healthcare, I believe its end markets will remain resilient even under tariff pressure. In short, tariffs represent a moderate headwind, but Danaher should largely neutralize the impact by expense reductions and operational flexibility. Margins in the upcoming quarters are expected to contract largely due to seasonality in Cepheid's respiratory testing business. Cepheid is one of Danaher's higher?margin units, and Q2 respiratory kit revenue is assumed to be only about $250 million (vs. ~$625 million in Q1). This sharp seasonal drop in high-margin sales, plus normal diagnostic restructuring costs (e.g., the management of China's reimbursement changes), drives the lower quarter?on?quarter profit margin. In sum, I believe the company's margins should continue to decline and improve in the back half of 2025. As a company built on decades of disciplined capital deployment, Danaher's ability to acquire and successfully integrate businesses has been one of its defining competitive advantages. Flagship acquisitions like Cepheid and Pall have meaningfully strengthened Danaher's diagnostics and bioprocessing platforms, but they also introduce inherent integration risks. These include short-term pressures on margins, incremental R&D and SG&A costs, and the complexities of aligning acquired operations with Danaher's operating structure. While such challenges are typical of any acquisitive strategy, Danaher's track record sets it apart. Over the past 30 years, the company has repeatedly demonstrated its ability to extract synergies, improve productivity, and scale acquisitions effectively, largely driven by the Danaher Business System (DBS). This system institutionalizes continuous improvement, cost efficiency, and cultural integration across its portfolio. Though former CEO Larry Culp played a pivotal role in establishing this M&A discipline, the company's current leadership remains strongly committed to DBS principles, which continue to guide its post-acquisition integration efforts. Moreover, Danaher doesn't pursue acquisitions purely for scale; it focuses on high-quality, strategic assets that complement existing platforms and offer long-term value creation. While integration may temporarily weigh on profitability, especially in the form of restructuring expenses, near-term dilution, or elevated investments in innovation, these are often calculated trade-offs for future operating leverage and market expansion. In essence, what might be viewed as a risk is also one of Danaher's greatest strengths; its consistent ability to turn acquired assets into high-margin, growth-focused businesses that reinforce its leadership in life sciences and diagnostics. As of March 31, 2025, investor activity around Danaher reflected a balanced mix of strategic repositioning and continued confidence in the company's long-term potential. Notably, renowned value investors like Joel Greenblatt (Trades, Portfolio) (+29.03%), Wallace Weitz (Trades, Portfolio) (+23.17%), and Arnold Van Den Berg (Trades, Portfolio) (+14.62%) significantly increased their holdings, signaling optimism about Danaher's focused life sciences and diagnostics trajectory. Ken Fisher (Trades, Portfolio) also added modestly to his position (+1.23%), reinforcing steady institutional support. While some investors like Jefferies Group (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), and George Soros (Trades, Portfolio) trimmed their stakes. Danaher is currently trading at a forward P/E of 25.5x and 22.9x on FY2025 and FY2026 estimated EPS of $7.70 and $8.57, respectively, which is below its five-year average forward P/E of 29.9x. On an EV/EBITDA basis, Danaher trades at approximately 18xhigher than peers such as Thermo Fisher Scientific (P/E ~15x, EV/EBITDA ~13x) and Agilent Technologies (P/E ~21x, EV/EBITDA ~15x). While Danaher's valuation premium may appear elevated relative to peers, it reflects the company's consistent execution, higher exposure to recurring revenue from consumables, and strong margin profile. The market seems cautiously optimistic, pricing in steady growth expectations. For FY2025, Danaher's outlook implies stable and controlled expansion, led primarily by strong bioprocessing demand. Although adjusted operating margins are expected to decline in Q2 due to seasonal normalization in the high-margin Cepheid business, a recovery is anticipated in the latter half of the year. Danaher's long-standing execution discipline, anchored by the Danaher Business System (DBS), equips it to offset macro pressures through operational efficiency and agile supply chain management. With a focused portfolio in mission-critical life sciences and diagnostics, Danaher remains well-positioned to deliver modest yet resilient growth in 2025, supported by strategic capital deployment and a strong competitive moat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Husband's Attempt at Humor During Ultrasound Backfires. Now He Is ‘Banned' from Speaking in Other Appointments
A husband decided to accompany his wife to her ultrasound appointment The pair were excited to hear their child's heartbeat for the first time However, the wife and doctor were not amused by the husband's joke after hearing the soundExpecting a child is one of life's most emotional and transformative experiences. For one Reddit user and his wife, both 31, the journey to parenthood took an unexpectedly awkward — yet humorous — turn during a routine ultrasound appointment. What began as a joyful, exciting day quickly became a moment of comic misfire that will likely be remembered for years to come. 'We went in for the 12-week scan. Everyone's in a good mood, the tech is sweet, and everything looks great,' the soon-to-be dad writes in the post, setting the stage for what was supposed to be a tender milestone in their pregnancy journey. But then came the moment that often brings tears to parents' eyes: the first sound of the baby's heartbeat. 'She puts the wand over my wife's belly, and the room goes quiet. Then: Lub dub. Lub dub,' he recalls. It was then, caught up in the emotion and the surreal quality of the moment, that the expectant father said what he thought would be a lighthearted comment to break the silence. "Without thinking, I blurt out, 'Sounds like a tiny rave in there,'' he recalls. Unfortunately, his attempt at humor didn't land. 'No one laughs. Not the tech. Not my wife,' he recounts. 'The tech just says flatly, 'It's a heart, not a party.' My wife, God bless her, gives me that 'please stop breathing for a second' look.' The silence that followed was deafening. What was meant to be a bonding moment through shared laughter turned into a lesson in timing — and the unwritten rules of ultrasound etiquette. Recognizing the situation, the dad decided to stay quiet for the rest of the appointment. Although no one found his comment funny at the moment, Reddit users flooded the comments in support of the poster. 'Ehhh they just don't have a sense of humor, that's pretty funny,' one person commented. 'Dad joking it up before you are officially a dad.' The fallout, however, didn't end at the clinic. Later that night, his wife sent him a text from another room. 'Tiny rave. Really?' she asked. The poster noted that he has since been 'permanently banned from speaking during future appointments." While the joke didn't garner any laughs, it did lead to an unofficial nickname for their future son. 'We're naming the baby Oliver,' he writes, 'but I know the real nickname will be DJ Heartbeat.' In the end, this expectant father learned a valuable — and slightly embarrassing — lesson: sometimes, the best thing to say during a poignant moment is nothing at all. Still, it's clear that his heart was in the right place, even if his timing was not. Read the original article on People
